Simvastatin in Critically Ill Patients with Covid-19.
null nullThomas E HillsElizabeth LorenziLindsay R BerryMurali ShyamsundarFarah Al-BeidhDjillali AnnaneYaseen ArabiDiptesh AryalCarly AuAbigail BeaneZahra BhimaniMarc BontenCharlotte Ann BradburyFrank M BrunkhorstAidan BurrellMeredith BuxtonCarolyn S CalfeeMaurizio CecconiAllen C ChengMatthew Edward CoveMichelle A DetryLise J EstcourtMark FitzgeraldEwan C GoligherHerman GoossensCameron GreenRashan HaniffaDavid A HarrisonMadiha HashmiAlisa M HigginsDavid T HuangNao IchiharaDeva JayakumarPeter S KrugerFrançois LamontagneLamprini LamproPatrick R LawlerJohn C MarshallAlexina J MasonAnna McGlothlinShay McGuinnessZoe K McQuiltenBryan J McVerryPaul R MounceySrinivas MurthyMatthew D NealAlistair D NicholCecilia M O'KaneRachael L ParkeJane C ParkerEbenezer RabindrarajanLuis Felipe ReyesKathryn M RowanHiroki SaitoMarlene SantosChristina T SaundersChristopher W SeymourManu Shankar-HariPratik SinhaB Taylor ThompsonAlexis F TurgeonAnne M TurnerFrank van van de VeerdonkSebastian WeisIan S YoungRyan ZarychanskiRoger J LewisColin J McArthurDerek C AngusScott M BerryLennie P G DerdeSteve A WebbAnthony C GordonDaniel Francis McAuleyPublished in: The New England journal of medicine (2023)
Although recruitment was stopped because cases had decreased, among critically ill patients with Covid-19, simvastatin did not meet the prespecified criteria for superiority to control. (REMAP-CAP ClinicalTrials.gov number, NCT02735707.).
Keyphrases